Navigation Links
OncoGenex Reports Second Quarter 2009 Financial Results
Date:8/6/2009

    Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the second quarter and six months ended June 30, 2009 and reviewed the Company's highlights for the second quarter of 2009.

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

The loss attributable to common shareholders for the second quarter increased to $4.6 million from $2.9 million in 2008. For the six months ended June 30, 2009 the loss attributable to common shareholders increased to $7.0 million from $5.4 million in 2008.

Research and development expenses for the second quarter increased to $3.6 million from $1.1 million in 2008. For the six months ended June 30, 2009 research and development expenses increased to $5.3 million from $2.0 million in 2008. The increases in 2009 were primarily due to manufacturing costs incurred in the first six months of 2009 associated with the development of our product candidates OGX-011 and OGX-427, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first six months of 2008 was a Scientific Research and Development (SRED) claim, which offset R D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company as a result of the reverse takeover, SRED claims can now only
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ ... its Board of Directors today declared a $0.61 per ... dividend will be paid on Sept. 5, 2014, to ... business on Aug. 14, 2014.  About ... biology for patients suffering from serious illnesses by discovering, ...
(Date:7/25/2014)... 2014 WABC Radio show out of New ... Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder and ... therapy in pets. Dr. Harman first visited the show ... therapy for pets suffering from osteoarthritis and other degenerative diseases, ... industry forward. , Young has invited Dr. Harman back to ...
(Date:7/25/2014)... At the request of the AMA, ... extension for the public comment period (Docket No. FAA-2014-0396) ... Aircraft established by Congress as part of the FAA ... establishes the new deadline for comments as September 23, ... notice published in the Federal Register on July 25, ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... Jan. 12 Synvista Therapeutics, Inc. (NYSE Alternext ... its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial ... measure the effect of alagebrium on exercise tolerance in patients ... completing enrollment of its BREAK ( B eginning a ...
... Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ... EYE ) announced,today a definitive agreement for Abbott to acquire ... value of approximately $2.8 billion, inclusive,of estimated net debt at ... AMO,is a global leader in ophthalmic care, comprised of three ...
... Bavarian Nordic,owns several United States patents relating ... MVA-BN(R), which is the basis for its smallpox,vaccine, ... for delivering,recombinant vaccines. Bavarian Nordic has asserted three ... The claim in this case is that Oxford,BioMedica ...
Cached Biology Technology:Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... of how wildlife loss leads to conflict among people ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of ... an interdisciplinary approach to tackle global biodiversity decline. , ... of the world,s people and provides protein for more ... come as no surprise that today,s unprecedented loss of ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3New study draws links between wildlife loss and social conflicts 2
... are succumbing to infection with canine distemper virus (CDV), a ... authors of a study published in mBio , the ... Pressure from poaching, decimation of their prey base, and ... called Siberian tigers) to fewer than 500. In the study, ...
... clinicians have an interest in how the cells of our ... to grow, to heal, to transmit information internally, to mount ... necessary for survival. But if cell mobility is unregulated, tumors ... multi-disciplinary study by University of Pennsylvania researchers has now illuminated ...
... 2013  Local Pearle Vision licensee, Theresa Ayers , has added ... with her husband, Ronald Ayers , the husband-and-wife team assumed ... Everhard Road N.W. Theresa Ayers has been with Pearle Vision, one ... licensed optical brands, for more than three decades. She began her ...
Cached Biology News:Canine distemper virus: An emerging disease in rare Amur tigers 2Multi-disciplinary Penn research identifies protein required for cell movement 2Multi-disciplinary Penn research identifies protein required for cell movement 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 2Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 3Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 4Local Pearle Vision Licensee Adds Second Center In Canton, Ohio 5
... GyroTwister GX-1000 3-D Shaker , ... shaking motion of the GyroTwister GX-1000 is ... ideal for general mixing as well as ... speed is continuously adjustable across a broad ...
...
... Radiochemical Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
...
Biology Products: